{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Esteroide oral", "Hyperbaric oxygen therapy", "Idiopathic sudden sensorineural hearing loss", "Oral steroid", "Oxigenoterapia hiperb\u00e1rica", "Ozone therapy", "Ozonioterapia", "Surdez s\u00fabita"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [{"AbstractText": ["\u00c9 dif\u00edcil avaliar o efeito dos f\u00e1rmacos clinicamente utilizados na surdez s\u00fabita idiop\u00e1tica, principalmente porque o seu mecanismo subjacente se mant\u00e9m desconhecido.", "Avaliar a efic\u00e1cia da oxigenoterapia hiperb\u00e1rica ou ozonioterapia no tratamento de surdez s\u00fabita, quando uma ou outra terapia \u00e9 inclu\u00edda no tratamento com esteroides.", "Uma an\u00e1lise retrospectiva examinou 106 pacientes com surdez s\u00fabita atendidos entre janeiro de 2010 e junho de 2012. Aqueles com uma etiologia identificada foram exclu\u00eddos. Os pacientes foram divididos em tr\u00eas grupos de tratamento: apenas esteroide oral (n\u00a0=\u00a065), esteroide por via oral\u00a0+\u00a0oxigenoterapia hiperb\u00e1rica (n\u00a0=\u00a026) e esteroides por via oral\u00a0+\u00a0oz\u00f4nio (n\u00a0=\u00a017). O sucesso do tratamento foi avaliado com crit\u00e9rios de Siegel e os ganhos m\u00e9dios com audiogramas pr\u00e9 e p\u00f3s-tratamento.", "A taxa de resposta mais elevada para o tratamento foi observada no grupo de esteroide\u00a0+\u00a0ozonioterapia (82,4%), seguida por grupos de esteroide oral\u00a0+\u00a0oxigenoterapia hiperb\u00e1rica (61,5%) e esteroide oral (50,8%). N\u00e3o houve diferen\u00e7as significantes na resposta ao tratamento entre os grupos de esteroide oral e esteroides\u00a0+\u00a0oxigenoterapia hiperb\u00e1rica (<i>p</i>\u00a0<\u00a00,355). O grupo de esteroide oral\u00a0+\u00a0oz\u00f4nio apresentou uma taxa de resposta significantemente mais elevada ao tratamento do que o grupo de esteroide oral (<i>p</i>\u00a0=\u00a00,019). N\u00e3o houve diferen\u00e7as significantes entre os grupos de esteroide oral\u00a0+\u00a0oxigenoterapia hiperb\u00e1rica e esteroide oral\u00a0+\u00a0oz\u00f4nio (<i>p</i>\u00a0=\u00a00,146).", "A efici\u00eancia do tratamento com esteroides em pacientes com perda auditiva grave foi baixa. Verificou-se estatisticamente que a adi\u00e7\u00e3o de oxigenoterapia hiperb\u00e1rica ou ozonioterapia ao tratamento contribuiu significantemente para o sucesso do tratamento."], "CopyrightInformation": "Copyright \u00a9 2016 Associa\u00e7\u00e3o Brasileira de Otorrinolaringologia e Cirurgia C\u00e9rvico-Facial. Published by Elsevier Editora Ltda. All rights reserved."}], "GeneralNote": [], "PMID": "27460341", "DateCompleted": {"Year": "2017", "Month": "07", "Day": "31"}, "DateRevised": {"Year": "2022", "Month": "09", "Day": "10"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2016", "Month": "07", "Day": "06"}], "ELocationID": ["10.1016/j.bjorl.2016.06.002", "S1808-8694(16)30129-X"], "Journal": {"ISSN": "1808-8686", "JournalIssue": {"Volume": "83", "Issue": "4", "PubDate": {"Year": "2017", "Season": "Jul-Aug"}}, "Title": "Brazilian journal of otorhinolaryngology", "ISOAbbreviation": "Braz J Otorhinolaryngol"}, "ArticleTitle": "The place of hyperbaric oxygen therapy and ozone therapy in sudden hearing loss.", "Pagination": {"StartPage": "457", "EndPage": "463", "MedlinePgn": "457-463"}, "Abstract": {"AbstractText": ["It is difficult to evaluate the effect of drugs clinically used for idiopathic sudden sensorineural hearing loss, mainly because its underlying mechanism remains unknown.", "This study assessed the efficacy of hyperbaric oxygen therapy or ozone therapy in the treatment of idiopathic sudden sensorineural hearing loss, when either therapy was included with steroid treatment.", "A retrospective analysis examined 106 patients with idiopathic sudden sensorineural hearing loss seen between January 2010 and June 2012. Those with an identified etiology were excluded. The patients were divided into three treatment groups: oral steroid only (n=65), oral steroid+hyperbaric oxygen (n=26), and oral steroid+ozone (n=17). Treatment success was assessed using Siegel criteria and mean gains using pre- and post-treatment audiograms.", "The highest response rate to treatment was observed in the oral steroid+ozone therapy group (82.4%), followed by the oral steroid+hyperbaric oxygen (61.5%), and oral steroid groups (50.8%). There were no significant differences in the response to treatment between the oral steroid and oral steroid+hyperbaric oxygen groups (p<0.355). The oral steroid+ozone group showed a significantly higher response rate to treatment than the oral steroid group (p=0.019). There were no significant differences between the oral steroid+hyperbaric oxygen and oral steroid+ozone groups (p=0.146).", "The efficiency of steroid treatment in patients with severe hearing loss was low. It was statistically ascertained that adding hyperbaric oxygen or ozone therapy to the treatment contributed significantly to treatment success."], "CopyrightInformation": "Copyright \u00a9 2016 Associa\u00e7\u00e3o Brasileira de Otorrinolaringologia e Cirurgia C\u00e9rvico-Facial. Published by Elsevier Editora Ltda. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Van Training And Research Hospital, Department of Otorhinolaryngology, Van, Turkey. Electronic address: gulinergun@gmail.com."}], "LastName": "Ergun Ta\u015fd\u00f6ven", "ForeName": "G\u00fclin", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Akdeniz University, School of Medicine, Department of Otorhinolaryngology, Antalya, Turkey."}], "LastName": "Derin", "ForeName": "Alper Tunga", "Initials": "AT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Akdeniz University, School of Medicine, Department of Otorhinolaryngology, Antalya, Turkey."}], "LastName": "Yaprak", "ForeName": "Neslihan", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Akdeniz University, School of Medicine, Department of Otorhinolaryngology, Antalya, Turkey."}], "LastName": "\u00d6z\u00e7a\u011flar", "ForeName": "Hasan \u00dcmit", "Initials": "H\u00dc"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Brazil", "MedlineTA": "Braz J Otorhinolaryngol", "NlmUniqueID": "101207337", "ISSNLinking": "1808-8686"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Steroids"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "CommentsCorrectionsList": [{"RefSource": "Braz J Otorhinolaryngol. 2017 Nov - Dec;83(6):732. doi: 10.1016/j.bjorl.2017.03.007", "PMID": "28476654"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Aged, 80 and over"}, {"QualifierName": [], "DescriptorName": "Audiometry"}, {"QualifierName": [], "DescriptorName": "Combined Modality Therapy"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["therapy"], "DescriptorName": "Hearing Loss, Sudden"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["methods"], "DescriptorName": "Hyperbaric Oxygenation"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Retrospective Studies"}, {"QualifierName": [], "DescriptorName": "Severity of Illness Index"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Steroids"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": [], "DescriptorName": "Young Adult"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "National Institute of Health . National Institutes of Health; Bethesda, MD: 2000. Sudden deafness. NIH publication 00-4757."}, {"Citation": "Byl F.M., Jr. Sudden hearing loss: 8 years\u2019 experience and suggested prognostic table. Laryngoscope. 1984;94:647\u2013661.", "ArticleIdList": ["6325838"]}, {"Citation": "Arts H.A. 3rd ed. vol. 4. Mosby-Year Book, Inc.; Philadelphia: 1998. Differential diagnosis of sensorineural hearing loss; pp. 2923\u20132928. (Cummings CW otolaryngology head & neck surgery)."}, {"Citation": "Byl F. 76 cases of presumed sudden hearing loss occurring in 1973: prognosis and incidence. Laryngoscope. 1977;87:817\u2013825.", "ArticleIdList": ["850455"]}, {"Citation": "Hughes G.B., Freedman M.A., Haberkamp T.J., Guay M.E. Sudden sensorineural hearing loss. Otolaryngol Clin North Am. 1996;29:393\u2013405.", "ArticleIdList": ["8743339"]}, {"Citation": "Fetterman B.L., Saunders J.E., Luxford W.M. Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol. 1996;17:529\u2013536.", "ArticleIdList": ["8841697"]}, {"Citation": "Moskowitz D., Lee K.J., Smith H.W. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope. 1984;94:664\u2013666.", "ArticleIdList": ["6717224"]}, {"Citation": "Siegel L.G. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin North Am. 1975;8:467\u2013473.", "ArticleIdList": ["1153209"]}, {"Citation": "WilsonWR, Byl F.M., Laird L.N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol. 1980;106:772\u2013776.", "ArticleIdList": ["7002129"]}, {"Citation": "Mattox D.E., Simmons F.B. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1977;86:463\u2013480.", "ArticleIdList": ["889223"]}, {"Citation": "Garc\u00eda Berrocal J.R., Ram\u00edrez-Camacho R. Immune response and immunopathology of the inner ear: an update. J Laryngol Otol. 2000;114:101\u2013107.", "ArticleIdList": ["10748824"]}, {"Citation": "Mort D.J., Bronstein A.M. Sudden deafness. Curr Opin Neurol. 2006;19:1\u20133.", "ArticleIdList": ["16415670"]}, {"Citation": "Erichsen S., Bagger-Sj\u00f6back D., Curtis L., Zuo J., Rarey K.E., Hultcrantz M. Appearence of glicocorticoid receptors in the inner ear of the mouse during development. Acta Otolaryngol. 1996;16:721\u2013724.", "ArticleIdList": ["8908249"]}, {"Citation": "Furuta H., Mori N., Sato C. Mineralocorticoid type I receptor in the rat cochlea: mRNA identification by polymerase chain reaction and in situ hybridization. Hear Res. 1994;78:175\u2013180.", "ArticleIdList": ["7982810"]}, {"Citation": "Lamm H., Klimpel L. Hyperbaric oxygen therapy in internal ear and vestibular disorders. Preliminary report. HNO. 1971;19:363\u2013369.", "ArticleIdList": ["5157138"]}, {"Citation": "Haupt H., Scheibe F., Ludwig C. Changes in cochlear oxygenation, microcirculation and auditory function during prolonged general hypoxia. Eur Arch Otorhinolaryngol. 1993;250:396\u2013400.", "ArticleIdList": ["8286104"]}, {"Citation": "Lamm K., Lamm H., Arnold W. Effect of hyperbaric oxygen therapy in comparison to conventional or placebo therapy or no treatment in idiopathic sudden hearing loss, acoustic trauma, noise-induced hearing loss and tinnitus. A literature survey. Adv Otorhinolaryngol. 1998;54:86\u201399.", "ArticleIdList": ["9547879"]}, {"Citation": "Fujimura T., Suzuki H., Shiomori T., Udaka T., Mori T. Hyperbaric oxygen and steroid therapy for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2007;264:861\u2013866.", "ArticleIdList": ["17340130"]}, {"Citation": "Alimoglu Y., Inci E., Edizer D.T., Ozdilek A., Aslan M. Efficacy comparison of oral steroid, intratympanic steroid, hyperbaric oxygen and oral steroid\u00a0+\u00a0hyperbaric oxygen treatments in idiopathic sudden sensorineural hearing loss cases. Eur Arch Otorhinolaryngol. 2011;268:1735\u20131741.", "ArticleIdList": ["21431435"]}, {"Citation": "Topuz E., Yi\u011fit O., Cinar U., Seven H. Should hyperbaric oxygen be added to treatment in idiopathic sudden sensorineural hearing loss? Eur Arch Otorhinolaryngol. 2004;261:393\u2013396.", "ArticleIdList": ["14586625"]}, {"Citation": "Bocci V. 2nd ed. Springer; Dordrecht, The Netherlands: 2011. OZONE. A new medical drug; pp. 23\u201324."}, {"Citation": "Baeuerle P.A., Henkel T. Function and activation of NF-\u03baB in the immune system. Annu Rev Immunol. 1994;12:141\u2013179.", "ArticleIdList": ["8011280"]}, {"Citation": "Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1977;336:1066\u20131071.", "ArticleIdList": ["9091804"]}, {"Citation": "Merchant S.N., Adams J.C., Nadol J.B., Jr. Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2005;26:151\u2013160.", "ArticleIdList": ["15793397"]}, {"Citation": "Di Paolo N., Gaggiotti E., Galli F. Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy. Redox Rep. 2005;10:121\u2013130.", "ArticleIdList": ["16156950"]}, {"Citation": "Ragab A., Shreef E., Behiry E., Zalat S., Noaman M. Randomised, doubleblinded, placebo-controlled, clinical trial of ozone therapy as treatment of sudden sensorineural hearing loss. J Laryngol Otol. 2009;123:54\u201360.", "ArticleIdList": ["18925995"]}, {"Citation": "S\u00f6nmez O., K\u00fclahl\u0131 I., Vural A., Sahin M.I., Ayd\u0131n M. The evaluation of ozone and betahistine in the treatment of tinnitus. Eur Arch Otorhinolaryngol. 2013;270:1999\u20132006.", "ArticleIdList": ["23100082"]}], "ReferenceList": []}], "History": [{"Year": "2016", "Month": "2", "Day": "15"}, {"Year": "2016", "Month": "5", "Day": "24"}, {"Year": "2016", "Month": "6", "Day": "2"}, {"Year": "2016", "Month": "7", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "8", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "7", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "7", "Day": "6"}], "PublicationStatus": "ppublish", "ArticleIdList": ["27460341", "PMC9442686", "10.1016/j.bjorl.2016.06.002", "S1808-8694(16)30129-X"]}}], "PubmedBookArticle": []}